Pluri Inc. share price logo

Pluri Inc.

NASDAQ: PLUR

Small Cap

$3.35

-0.13

(-3.76%)

as on

Pluri Inc. Stock Performance

as on May 2, 2026 at 5:06 am IST

  • Day's High

    $3.35
    $3.49

    4.18%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $2.82
    $6.10
    downward going graph

    15.82%

    Downside

    82.09%

    Upside

    downward going graph

Pluri Inc. share price movements today

Previous Close
$3.48
Open
$3.46
Volume
38.8K
Day's Low - High
$3.35 - $3.49
52 Week Low - High
$2.82 - $6.10

Pluri Inc. Historical Returns

1 Month Return
+ 0.9 %
3 Month Return
+ 1.21 %
1 Year Return
-31.58 %
3 Year Return
-58.13 %
5 Year Return
0 %

Pluri Inc. Stock Fundamentals & Key Indicators

Check Pluri Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$36.1M

EPS (TTM)

-2.7

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-24.4M

Revenue (TTM)

1.3M

Profit Margin

0.00%

Return On Equity TTM

-1021.98%

Pluri Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Pluri Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Pluri Inc. image
Pluri Inc.
BUY$36.1MNANA0.00%
Alnylam Pharmaceuticals Inc image
Alnylam Pharmaceuticals Inc
BUY$41.3B110.54%77.5712.55%
Vertex Pharmaceuticals Inc image
Vertex Pharmaceuticals Inc
BUY$108.7B94.28%27.9332.94%
BeiGene, Ltd. image
BeiGene, Ltd.
NA$32.7BNA118.495.37%
Regeneron Pharmaceuticals Inc image
Regeneron Pharmaceuticals Inc
BUY$74.1B45.73%17.2729.65%

Stock Returns calculator for Pluri Inc. Stock including INR - Dollar returns

The Pluri Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

Pluri Inc. investment value today

Current value as on today

₹76,977

Returns

-₹23,023

(-23.02%)

Returns from Pluri Inc. Stock

-₹31,633 (-31.63%)

Dollar Impact

₹8,610 (+8.61%)

Analyst Recommendation on Pluri Inc. Stock

Based on 7 analysts

BUY

85.71%

Buy

14.29%

Hold

0.00%

Sell

Based on 7 analysts, 85.71% of analysts recommend a 'BUY' rating for Pluri Inc.. Average target price of $12

Pluri Inc. Share Price Target

Get share price movements and forecasts by analysts on Pluri Inc..

What analysts predicted

72.08%UPSIDE

Target Price

$12

Current Price

$3.35

Analyzed by

7 Analysts

Target

$12.00

Pluri Inc. target price $12, a slight upside of 72.08% compared to current price of $3.35. According to 7 analysts rating.

Pluri Inc. Stock’s Investor Sentiment and Interest

Search interest for Pluri Inc. Stock has increased by 20% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:20% versus previous 30 day period

Pluri Inc. Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
0
0
0
0
0
0
0
0
0
0
Gross Profit
0
0
0
0
0
0
0
0
0
0
Operating Income
-5
-5
-5
-6
-5
-4
-5
-6
-6
-6
EBITDA
-4
-4
-5
-5
-5
-2
-6
-7
-6
-6
Interest Expense
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-5
-4
-5
-5
-6
-3
-6
-7
-6
-6
Income Tax Expense
0
0
0
0
-
-
-
0
0
0
Net Income
-4
-4
-5
-5
-5
-2
-6
-7
-5
-6
Net Profit Margin
-9187.04%
-4671.43%
-7454.93%
-5967.71%
-1804.29%
-1597.84%
-1439.58%
-1909.05%
-1851.27%
-3304.55%

Pluri Inc. Annual Profit & Loss

All numbers in Millions USD

Jun 2016
Jun 2018
Jun 2019
Jun 2020
Jun 2021
Jun 2022
Jun 2023
Jun 2024
Jun 2025
Total Revenue
2
0
0
0
-
0
0
0
1
Gross Profit
2
0
0
-1
-1
0
0
0
0
Operating Income
-23
-33
-35
-29
-50
-41
-27
-22
-22
EBITDA
-21
-24
-33
-27
-48
-39
-27
-20
-22
Interest Expense
0
0
0
0
0
0
0
0
0
Depreciation
-
-
1
1
1
1
0
0
0
Income Before Tax
-23
-26
-35
-29
-49
-41
-28
-21
-23
Income Tax Expense
0
7
0
0
0
0
0
0
0
Net Income
-23
-26
-35
-29
-49
-41
-28
-20
-22
Net Profit Margin
-816.51%
-52252.00%
-65383.33%
-126747.83%
0.00%
-17624.79%
-9867.94%
-6407.36%
-1690.34%

Pluri Inc. Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-4
-5
-5
-6
-3
-6
-7
-6
-6
Operating Cash Flow
-3
-4
-4
-4
-4
-4
-5
-5
-5
Investing Cash Flow
3
5
-4
0
8
-4
3
3
2
Financing Cash Flow
-
-
8
-
-7
9
0
-
2
Change in Cash
0
1
0
-3
4
1
-2
-1
0

Pluri Inc. Annual Cash Flow

All numbers in Millions USD

Jun 2017
Jun 2018
Jun 2019
Jun 2020
Jun 2021
Jun 2022
Jun 2023
Jun 2024
Jun 2025
Net Income
-27
-26
-35
-29
-49
-41
-28
-21
-23
Operating Cash Flow
-21
-21
-29
-26
-30
-36
-22
-18
-18
Investing Cash Flow
4
5
1
-30
-7
11
9
10
8
Financing Cash Flow
15
19
23
60
61
7
8
8
9
Change in Cash
-1
4
-4
4
22
-20
-5
1
0

Global Institutional Holdings in Pluri Inc.

Funds
Holdings
Morgan Stanley - Brokerage Accounts
0.03%
Wells Fargo & Co
0%
SBI Securities Co Ltd
0%
SBI Securities Co Ltd
0%
IFP Advisors, LLC
0%
See all

Insights on Pluri Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 15.8% return, outperforming this stock by 47.4%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Pluri Inc has experienced a drawdown of -57.7%, however Alnylam Pharmaceuticals, Inc. resisted the overall trend and outperformed by 45.0%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 4 quarters, 427.0K → 198.0K (in $), with an average decrease of 21.6% per quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -5.85M → -6.54M (in $), with an average decrease of 11.9% per quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 3 years, PLUR stock has moved down by -57.7%

About Pluri Inc.

Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. The company's product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and is in Phase I clinical trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. It also offers cell manufacturing services and cell-based coffee; and develops and commercializes cultivated meat products. The company operates in the field of regenerative medicine, food tech, immunotherapy, CDMO, and AgTech. It has collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
OrganisationPluri Inc.
HeadquartersMATAM Advanced Technology Park, Haifa, Israel, 3508409
IndustryBiotechnology
CEOMr. Yaacov Yanay
E-voting on sharesClick here to vote

Key Management of Pluri Inc.

Name

Title

Mr. Ori Shalem

Vice President of Operations & Manufacturing

Mr. Lior Raviv

Chief Technology Officer

Dr. Arthur Machlenkin Ph.D.

Chief Scientific Officer

Ms. Nofar Glaich-Dabach

Vice President of Human Resources

Mr. Yaacov Yanay

President, CEO & Director

Ms. Hagit Gal

General Counsel

Ms. Orly Amiran

Chief Quality Officer

Ms. Efrat Kaduri

Chief Business Development Officer of Pharma

Mr. Nimrod Bar Zvi

Chief Commercial Officer

FAQs

What is Pluri Inc. share price today?

Pluri Inc. share price today is $3.35 as on at the close of the market. Pluri Inc. share today touched a day high of $3.49 and a low of $3.35.

What is the 52 week high and 52 week low for Pluri Inc. share?

Pluri Inc. share touched a 52 week high of $6.1 on and a 52 week low of $2.82 on . Pluri Inc. stock price today i.e. is closed at $3.35,which is 45.08% down from its 52 week high and 18.79% up from its 52 week low.

What is Pluri Inc.'s market capitalisation today?

Pluri Inc. market capitalisation is $0.00T as on .

How to invest in Pluri Inc. Stock (PLUR) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Pluri Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Pluri Inc. Shares that will get you 0.4478 shares as per Pluri Inc. share price of $3.35 per share as on May 1, 2026 at 11:36 pm IST.

What is the minimum amount required to buy Pluri Inc. Stock (PLUR) from India?

Indian investors can start investing in Pluri Inc. (PLUR) shares with as little as ₹94.91 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.10 in Pluri Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Pluri Inc. share’s latest price of $3.35 as on May 1, 2026 at 11:36 pm IST, you will get 2.9851 shares of Pluri Inc.. Learn more about fractional shares .